Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,236 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Functional mapping of androgen receptor enhancer activity.
Huang CF, Lingadahalli S, Morova T, Ozturan D, Hu E, Yu IPL, Linder S, Hoogstraat M, Stelloo S, Sar F, van der Poel H, Altintas UB, Saffarzadeh M, Le Bihan S, McConeghy B, Gokbayrak B, Feng FY, Gleave ME, Bergman AM, Collins C, Hach F, Zwart W, Emberly E, Lack NA. Huang CF, et al. Genome Biol. 2021 May 11;22(1):149. doi: 10.1186/s13059-021-02339-6. Genome Biol. 2021. PMID: 33975627 Free PMC article.
Development of an Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate Cancer.
Ban F, Leblanc E, Cavga AD, Huang CF, Flory MR, Zhang F, Chang MEK, Morin H, Lallous N, Singh K, Gleave ME, Mohammed H, Rennie PS, Lack NA, Cherkasov A. Ban F, et al. Among authors: huang cf. Cancers (Basel). 2021 Jul 12;13(14):3488. doi: 10.3390/cancers13143488. Cancers (Basel). 2021. PMID: 34298700 Free PMC article.
Development of 2-(5,6,7-Trifluoro-1H-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer.
Leblanc E, Ban F, Cavga AD, Lawn S, Huang CF, Mohan S, Chang MEK, Flory MR, Ghaidi F, Lingadahalli S, Chen G, Yu IPL, Morin H, Lallous N, Gleave ME, Mohammed H, Young RN, Rennie PS, Lack NA, Cherkasov A. Leblanc E, et al. Among authors: huang cf. J Med Chem. 2021 Oct 28;64(20):14968-14982. doi: 10.1021/acs.jmedchem.1c00681. Epub 2021 Oct 18. J Med Chem. 2021. PMID: 34661404
Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence.
Linder S, Hoogstraat M, Stelloo S, Eickhoff N, Schuurman K, de Barros H, Alkemade M, Bekers EM, Severson TM, Sanders J, Huang CF, Morova T, Altintas UB, Hoekman L, Kim Y, Baca SC, Sjöström M, Zaalberg A, Hintzen DC, de Jong J, Kluin RJC, de Rink I, Giambartolomei C, Seo JH, Pasaniuc B, Altelaar M, Medema RH, Feng FY, Zoubeidi A, Freedman ML, Wessels LFA, Butler LM, Lack NA, van der Poel H, Bergman AM, Zwart W. Linder S, et al. Among authors: huang cf. Cancer Discov. 2022 Sep 2;12(9):2074-2097. doi: 10.1158/2159-8290.CD-21-0576. Cancer Discov. 2022. PMID: 35754340 Free PMC article.
Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulation.
Baca SC, Singler C, Zacharia S, Seo JH, Morova T, Hach F, Ding Y, Schwarz T, Huang CF, Anderson J, Fay AP, Kalita C, Groha S, Pomerantz MM, Wang V, Linder S, Sweeney CJ, Zwart W, Lack NA, Pasaniuc B, Takeda DY, Gusev A, Freedman ML. Baca SC, et al. Among authors: huang cf. Nat Genet. 2022 Sep;54(9):1364-1375. doi: 10.1038/s41588-022-01168-y. Epub 2022 Sep 7. Nat Genet. 2022. PMID: 36071171 Free PMC article.
Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential.
Kneppers J, Severson TM, Siefert JC, Schol P, Joosten SEP, Yu IPL, Huang CF, Morova T, Altıntaş UB, Giambartolomei C, Seo JH, Baca SC, Carneiro I, Emberly E, Pasaniuc B, Jerónimo C, Henrique R, Freedman ML, Wessels LFA, Lack NA, Bergman AM, Zwart W. Kneppers J, et al. Among authors: huang cf. Nat Commun. 2022 Nov 30;13(1):7367. doi: 10.1038/s41467-022-35135-2. Nat Commun. 2022. PMID: 36450752 Free PMC article.
Breast cancer risk SNPs converge on estrogen receptor binding sites commonly shared between breast tumors to locally alter estrogen signalling output.
Joosten SE, Gregoricchio S, Stelloo S, Yapıcı E, Huang CF, Collier MD, Morova T, Altintas B, Kim Y, Canisius S, Korkmaz G, Lack N, Vermeulen M, Linn SC, Zwart W. Joosten SE, et al. Among authors: huang cf. bioRxiv [Preprint]. 2023 Nov 2:2023.10.30.564691. doi: 10.1101/2023.10.30.564691. bioRxiv. 2023. Update in: Genome Res. 2024 May 15;34(4):539-555. doi: 10.1101/gr.278680.123 PMID: 37961147 Free PMC article. Updated. Preprint.
Estrogen receptor 1 chromatin profiling in human breast tumors reveals high inter-patient heterogeneity with enrichment of risk SNPs and enhancer activity at most-conserved regions.
Joosten SEP, Gregoricchio S, Stelloo S, Yapıcı E, Huang CF, Yavuz K, Donaldson Collier M, Morova T, Altintaş UB, Kim Y, Canisius S, Moelans CB, van Diest PJ, Korkmaz G, Lack NA, Vermeulen M, Linn SC, Zwart W. Joosten SEP, et al. Among authors: huang cf. Genome Res. 2024 May 15;34(4):539-555. doi: 10.1101/gr.278680.123. Genome Res. 2024. PMID: 38719469 Free PMC article.
1,236 results